What Гутрон Treats: Main Uses and Benefits

Гутрон (Midodrine) is an antihypotensive agent applied across domains where additional symptomatic support is needed for low blood pressure that occurs when a patient stands up. This medication is generally considered relevant when symptoms that interfere with daily functioning are present, and it focuses on providing symptomatic support when the patient is in an upright position.

It is commonly used across conditions presenting with acute episodes of low blood pressure upon rising. It is used in situations involving certain distressing symptoms, where it helps address symptom clusters that may appear suddenly or fluctuate, such as dizziness, lightheadedness, and fainting spells. It is also applied in settings where short-term symptomatic assistance is important, especially when severe symptoms are experienced despite first-line non-pharmacological methods.

By managing these symptoms, Гутрон provides support that helps ease the overall symptom burden, contributes to improved comfort during symptomatic periods, and assists with maintaining functional stability.

Quick Fact: Relief for Postural Symptoms

Гутрон is commonly used across conditions presenting with acute episodes of postural low blood pressure, where its primary benefit is to support functional stability and help patients cope more steadily with symptom fluctuations upon standing.

Regulatory References

1. NIH MedlinePlus overview

The eligibility for Гутрон (Midodrine) is strictly defined by regulatory bodies to manage risks associated with its blood pressure-raising action. It is officially allowed for use in adults with severe symptomatic orthostatic hypotension due to autonomic dysfunction, provided non-pharmacologic measures have been inadequate.

Absolute Contraindications (Must Not Use)

Use is strictly prohibited in populations with specific high-risk health issues as defined in regulatory labeling:

• Cardiovascular: Persistent and excessive supine hypertension or severe organic heart disease (e.g., congestive heart failure, cardiac conduction disturbances).
• Organ Function: Acute renal disease or severe renal insufficiency (creatinine clearance less than 30 mL/min).
• Endocrine/Urological: Pheochromocytoma, Thyrotoxicosis, or pre-existing conditions that cause urinary retention.

Restricted and Not Recommended Populations

• Pediatric Population: Use is not recommended in children under 18 years due to insufficient safety and effectiveness data.
• Older Adults: Use is conditional, requiring verified adequate renal and hepatic function.
• Reproductive Status: Use is not recommended during pregnancy or lactation, and women of childbearing potential should use effective contraception.
• Organ Impairment: Caution is required for use in patients with mild to moderate renal or hepatic impairment, necessitating close function monitoring.

Interactions with other medicines and products

Midodrine’s interaction profile is officially defined by its pressor effects and its specific clearance mechanisms, as documented in regulatory sources.

Pharmacodynamic Restrictions Co-administration with Sympathomimetic Vasoconstrictor Agents or Monoamine Oxidase Inhibitors (MAOIs) should be avoided due to the documented risk of excessive hypertension. Combination with Cardiac Glycosides (e.g., Digitalis) is not recommended because the risk of potentiated bradycardia and heart block is significantly increased. The effects of the medicine are subject to antagonism by co-administered alpha-Adrenergic Antagonists. Corticosteroid preparations may enhance hypertensive effects and increase the documented risk of glaucoma/increased Intraocular Pressure (IOP).

Metabolic and Pharmacokinetic Constraints The active metabolite, desglymidodrine, is an inhibitor of CYP2D6, which may decrease the clearance and increase the systemic exposure of other medicines metabolized by this enzyme. Conversely, drugs that compete for renal tubular clearance (e.g., Amiodarone) can also increase Midodrine levels. A mandatory administration rule requires the last daily dose must be taken at least 4 hours before bedtime to mitigate the severe interaction risk associated with the patient's change to the supine position. Caution is required in patients with mild to moderate renal impairment due to the potential for active metabolite accumulation.

Alpha-1 Adrenergic Receptor Activation

Гутрон functions as a pro-drug, and its pharmacological activity is mediated by the active metabolite, desglymidodrine. This metabolite acts as an agonist (stimulator) at the post-synaptic alpha1-adrenergic receptors. These receptors are densely expressed on the smooth muscle cells lining the peripheral arterioles and veins.

Peripheral Vasoconstriction and Tonal Regulation

Stimulation of the alpha1-adrenergic receptors initiates an intracellular signaling cascade that culminates in the contraction of the vascular smooth muscle. This localized action produces a systemic narrowing of the blood vessels, resulting in an increase in peripheral vascular resistance and a subsequent elevation in overall systemic blood pressure.

Systemic Hemodynamic Effects

Desglymidodrine exhibits poor penetration of the blood-brain barrier, localizing its primary effects to the peripheral circulation. The resulting elevation in systemic blood pressure contributes to an altered baroreflex response via pressure modulation in the peripheral vasculature.

The administration of Гутрон (Midodrine) follows prescribing guidelines that define the dosage and schedule. The medicine is formulated as solid oral tablets available in strengths of 2.5 mg, 5 mg, and 10 mg.

Standard Administration Principles

Dose Adjustment and Procedural Protocol

Dosage adjustment, or titration, is a procedural step detailed in prescribing information. Treatment typically begins with a starting dose that may be gradually increased in 2.5 mg increments three times daily, usually at approximately weekly intervals, until the appropriate maintenance dose is achieved. This process is conducted under medical supervision.

For specific patient groups, established protocols outline starting dose modifications. Treatment in patients with impaired renal function is typically initiated at a lower dose of 2.5 mg. Furthermore, it is indicated that the safety and efficacy of Midodrine have not been established for use in pediatric patients. If a dose is missed, the standard instruction is to continue with the next scheduled dose as usual, without doubling the next dose.

Research Evidence / Overview of Studies

Summary of Key Findings

Clinical studies primarily focusing on orthostatic hypotension (OH) due to autonomic dysfunction have investigated midodrine, the active ingredient in Гутрон. Research has consistently observed that midodrine may lead to an increase in standing systolic blood pressure (SBP), a surrogate marker often used to assess efficacy in this condition. This increase in SBP after standing up is considered a main endpoint in many trials.

Studies also evaluated the effect of midodrine on key OH symptoms, such as dizziness, lightheadedness, and fainting. Data suggests that the medication may be associated with improvement in these symptoms, as reported by both patients and investigators in various assessments.

Study Design and Safety Profile

Early clinical development primarily relied on short-term, randomized, placebo-controlled trials. These trials documented a dose-dependent pressor effect that is noticeable within 30 to 45 minutes of administration and peaks approximately one hour after consumption. The effect generally lasts for 4 to 5 hours.

Midodrine is metabolized into its active component, desglymidodrine, which acts on peripheral alpha-1 adrenergic receptors to tighten blood vessels and increase blood pressure. The drug's safety and tolerability are generally considered acceptable when managed carefully, but the risk of supine hypertension is a frequently noted concern that necessitates regular monitoring.

Common questions about Гутрон (FAQ)

Q: What is the main use of Гутрон?

A: Гутрон (Midodrine) is a medication approved for the management of symptomatic orthostatic hypotension (OH). This condition involves a drop in blood pressure upon standing, which can cause symptoms such as dizziness or light-headedness. It is typically reserved for patients whose symptoms are severe and have not improved sufficiently with other non-pharmacologic measures.

Q: What should I know about taking Гутрон?

A: When prescribing Гутрон, healthcare providers typically advise against taking a dose late in the evening or close to bedtime. This precaution is advised because the medication can cause a significant rise in blood pressure when lying down (supine hypertension), which may occur after the medication is absorbed.

Q: Is Гутрон considered a safe treatment for low blood pressure?

A: Гутрон is associated with several potential side effects that should be discussed with a healthcare provider. The most serious risk is the development of supine hypertension, which is an elevation of blood pressure while lying flat. Other commonly observed side effects may include piloerection (goosebumps or tingling sensation), urinary retention, and headache.

Q: Does Гутрон work faster or better than other treatments for orthostatic hypotension?

A: Clinical data suggest that Гутрон may be associated with an increase in both systolic and diastolic blood pressure in the upright position for certain patients. It is one of several pharmacologic options available for orthostatic hypotension. The selection of treatment often depends on a patient's individual profile, the severity of their symptoms, and their response to other interventions, including non-drug treatments.

Storage and Disposal of Gutron (Midodrine Hydrochloride)

Gutron tablets must be stored according to regulatory requirements to maintain product stability and safety. The medicine should be kept at Controlled Room Temperature, not exceeding 25 C (77 F), and must not be frozen.

Required Conditions

Tablets must not be used after the expiry date (EXP) printed on the package has passed. All storage rules are defined to ensure the integrity of the active ingredient until the time of use.